B
Bullisch
Bullisch · 25%FLGT
$27.78
Szenariopreis
$19.810
-1.420 (-7.17%)Zum Schluss
Loading chart…
- Hoch
- 21.490
- Eröffnung
- 21.450
- Volumengewichteter Durchschnittskurs
- 20.34
- Volumen
- 443.37K
- Marktkap.
- 601.48M
- Tief
- 19.730
- Umsatz
- 9.02M
- EV/EBITDA, TTM
- -4.57
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
KI-Analyse of Fulgent Genetics Inc (FLGT)
HaltenFulgent Genetics Inc is currently priced at $21.74, which is above the recent analyst target of $19, indicating potential overvaluation. The stock has a forward P/E of 7.70, suggesting it may be undervalued compared to its earnings potential, but the company has reported significant losses, with a net income of -29.53 million in Q2 2026. The RSI is at 56.55, indicating a neutral momentum, and the stock has seen a 5-day change of +1.21%, showing some short-term strength. However, hedge funds are selling, with a 169.46% increase in selling activity, which raises concerns about future performance. Therefore, while there are some positive indicators, the risks associated with ongoing losses and negative sentiment from hedge funds suggest a cautious approach, leading to a recommendation to hold rather than buy.
Analystenbewertungen (3)
+64.06% Aufwärtspotenzial
Kaufen
2 Kaufen
1 Halten
0 Verkaufen
Aktuell: 19.81
Tief
30.00
Durchschnitt
32.50
Hoch
35.00
Piper Sandler
Neutral
$19
2026-08-04
Piper Sandler
2026-08-04
Kursziel
$19
Neutral
Piper Sandler
Neutral
$15
2026-05-05
Piper Sandler
2026-05-05
Kursziel
$15
Neutral
UBS
Kaufen
$22
2026-03-02
UBS
2026-03-02
Kursziel
$22
Kaufen
Piper Sandler
Neutral
$30
2025-11-11
Piper Sandler
2025-11-11
Kursziel
$30
Neutral
UBS
Kaufen
$30
2025-08-05
UBS
2025-08-05
Kursziel
$30
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Fulgent Genetics Inc (FLGT) beträgt 7.70, verglichen mit dem 5-Jahres-Durchschnitt von -36.97.
Alphio-AI-Kursszenarien für FLGT
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.006-01NewsfilterFulgent Genetics Presents Updated Data at ASCO Meeting
7.005-22GlobenewswireFulgent Genetics Under Investigation for Securities Violations
- 7.005-08Newsfilter
Fulgent Genetics Under Investigation for Securities Violations
7.005-08GlobenewswireFulgent Genetics Under Investigation for Securities Violations
9.505-01seekingalphaFulgent Genetics Q1 2026 Earnings Call Insights
FLGT FAQ – beantwortet von Alphio AI
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Fulgent Genetics Inc is currently priced at $21.74, which is above the recent analyst target of $19, indicating potential overvaluation. The stock has a forward P/E of 7.70, suggesting it may be undervalued compared to its earnings potential, but the company has reported significant losses, with a net income of -29.53 million in Q2 2026. The RSI is at 56.55, indicating a neutral momentum, and the stock has seen a 5-day change of +1.21%, showing some short-term strength. However, hedge funds are selling, with a 169.46% increase in selling activity, which raises concerns about future performance. Therefore, while there are some positive indicators, the risks associated with ongoing losses and negative sentiment from hedge funds suggest a cautious approach, leading to a recommendation to hold rather than buy.
3 analysts cover FLGT: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.50.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.